InsiderTrades.com logo
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.

Shawn Cross Biography and Net Worth

CFO of Applied Molecular Transport
  • LinkedIn
  • Phone
  • Email
  • Website


Shawn joined AMT as chief financial officer in 2020 where he leads the company’s finance strategy and oversees financial operations. He brings over 20 years of biopharmaceutical strategic advisory and capital market experience. Prior to joining AMT, Mr. Cross was at JMP Securities where he served as managing director and co-head of healthcare investment banking. Previously, Shawn held various investment banking roles at top financial institutions in New York, London, and San Francisco including managing director in healthcare investment banking at Deutsche Bank Securities, managing director and head of biopharmaceutical investment banking at Wells Fargo Securities, amongst others. He also brings operational experience from his time on the executive management team at GT Biopharma, a targeted immunotherapies company. Shawn holds an M.B.A. from Columbia Business School and a B.S. from the University of California, Los Angeles.

What is Shawn Cross' net worth?

The estimated net worth of Shawn Cross is at least $143,466.24 as of November 22nd, 2023. Mr. Cross owns 545,499 shares of Applied Molecular Transport stock worth more than $143,466 as of April 25th. This net worth estimate does not reflect any other assets that Mr. Cross may own. Additionally, Mr. Cross receives an annual salary of $679,780.00 as CFO at Applied Molecular Transport. Learn More about Shawn Cross' net worth.

How old is Shawn Cross?

Mr. Cross is currently 56 years old. There are 2 older executives and no younger executives at Applied Molecular Transport. Learn More on Shawn Cross' age.

What is Shawn Cross' salary?

As the CFO of Applied Molecular Transport Inc., Mr. Cross earns $679,780.00 per year. The highest earning executive at Applied Molecular Transport is Dr. Tahir Mahmood Ph.D., Co-Founder & Director, who commands a salary of $870,290.00 per year. Learn More on Shawn Cross' salary.

How do I contact Shawn Cross?

The corporate mailing address for Mr. Cross and other Applied Molecular Transport executives is 1 TOWER PLACE SUITE 850, SOUTH SAN FRANCISCO CA, 94080. Applied Molecular Transport can also be reached via phone at 650-392-0420 and via email at [email protected]. Learn More on Shawn Cross' contact information.

Has Shawn Cross been buying or selling shares of Applied Molecular Transport?

Shawn Cross has not been actively trading shares of Applied Molecular Transport within the last three months. Most recently, Shawn Cross sold 110,802 shares of the business's stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $0.16, for a transaction totalling $17,728.32. Following the completion of the sale, the chief executive officer now directly owns 545,499 shares of the company's stock, valued at $87,279.84. Learn More on Shawn Cross' trading history.

Who are Applied Molecular Transport's active insiders?

Applied Molecular Transport's insider roster includes Elizabeth Bhatt (Insider), Shawn Cross (CFO), Bittoo Kanwar (Insider), Helen Kim (Director), David Lamond (Director), Tahir Mahmood (CEO), Randall Mrsny (Insider), and Aaron VanDevender (Director). Learn More on Applied Molecular Transport's active insiders.

Are insiders buying or selling shares of Applied Molecular Transport?

During the last twelve months, insiders at the sold shares 14 times. They sold a total of 1,097,868 shares worth more than $176,549.76. The most recent insider tranaction occured on November, 22nd when CEO Shawn Cross sold 110,802 shares worth more than $17,728.32. Insiders at Applied Molecular Transport own 15.9% of the company. Learn More about insider trades at Applied Molecular Transport.

Information on this page was last updated on 11/22/2023.

Shawn Cross Insider Trading History at Applied Molecular Transport

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2023Sell110,802$0.16$17,728.32545,499View SEC Filing Icon  
11/15/2023Sell90,447$0.16$14,471.52656,301View SEC Filing Icon  
9/29/2023Sell193,960$0.16$31,033.60752,307View SEC Filing Icon  
9/5/2023Sell1,253$0.21$263.13746,748View SEC Filing Icon  
6/2/2023Sell4,306$0.24$1,033.44748,001View SEC Filing Icon  
12/2/2022Sell3,893$1.05$4,087.6561,090View SEC Filing Icon  
6/1/2022Sell1,767$2.97$5,247.9967,983View SEC Filing Icon  
8/23/2021Sell9,700$30.12$292,164.00300View SEC Filing Icon  
8/19/2021Sell300$30.01$9,003.00300View SEC Filing Icon  
See Full Table

Shawn Cross Buying and Selling Activity at Applied Molecular Transport

This chart shows Shawn Cross's buying and selling at Applied Molecular Transport by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Applied Molecular Transport Company Overview

Applied Molecular Transport logo
Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.
Read More

Today's Range

Now: $0.26
Low: $0.26
High: $0.26

50 Day Range

MA: $0.24
Low: $0.16
High: $0.31

2 Week Range

Now: $0.26
Low: $0.13
High: $0.84

Volume

N/A

Average Volume

470,969 shs

Market Capitalization

$10.87 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28
World’s biggest multibillionaire investor is buying THIS by the ton [picture]
From Stansberry Research   |   Ad
Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.
Click here to find out what to do.